International technology and health media Tech Times recently featured Immunwork’s long-acting GLP-1 receptor agonist TE-8105, highlighting its First-in-Human clinical results
Dr. Tse-Wen Chang, Chairman and Founder of Immunwork and T-E Meds, built his scientific career through National Tsing-Hua University, Harvard
In 2025, Immunwork successfully reached key clinical trial milestones for two drug candidates, TE-8105 and TE-8214. In an exclusive interview
T-E Meds has distinguished itself from a highly competitive pool of global nominees and has been selected as one of
The 2024 Tang Prize in Biopharmaceutical Science has cast a spotlight on GLP-1 receptor agonists, sparking a global race among
Congratulations to our founder, Dr. Tse-Wen Chang, the inventor of Xolair.We are thrilled to learn that Xolair’s potential benefits are extending
Website link: https://news.gbimonthly.com/tw/article/show.php?num=64320
Reported link: https://www.ctee.com.tw/news/20230925700053-439901
Website link: https://news.gbimonthly.com/tw/article/show.php?num=60662&utm_source=dable
Reported link: https://news.gbimonthly.com/tw/audiovisual/show.php?num=59755
